Savant Capital LLC Cuts Holdings in Jazz Pharmaceuticals PLC $JAZZ

Savant Capital LLC lowered its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 26.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,221 shares of the specialty pharmaceutical company’s stock after selling 801 shares during the period. Savant Capital LLC’s holdings in Jazz Pharmaceuticals were worth $236,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also made changes to their positions in the company. Teacher Retirement System of Texas raised its holdings in Jazz Pharmaceuticals by 0.6% in the second quarter. Teacher Retirement System of Texas now owns 15,560 shares of the specialty pharmaceutical company’s stock valued at $1,651,000 after acquiring an additional 90 shares in the last quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych raised its holdings in shares of Jazz Pharmaceuticals by 8.7% in the 2nd quarter. Generali Investments Towarzystwo Funduszy Inwestycyjnych now owns 1,250 shares of the specialty pharmaceutical company’s stock valued at $133,000 after purchasing an additional 100 shares in the last quarter. Sound View Wealth Advisors Group LLC lifted its position in shares of Jazz Pharmaceuticals by 1.3% during the 1st quarter. Sound View Wealth Advisors Group LLC now owns 8,425 shares of the specialty pharmaceutical company’s stock worth $1,046,000 after purchasing an additional 110 shares during the last quarter. Assetmark Inc. grew its stake in shares of Jazz Pharmaceuticals by 16.0% during the first quarter. Assetmark Inc. now owns 843 shares of the specialty pharmaceutical company’s stock worth $105,000 after purchasing an additional 116 shares in the last quarter. Finally, Securian Asset Management Inc. grew its stake in shares of Jazz Pharmaceuticals by 2.7% during the second quarter. Securian Asset Management Inc. now owns 4,694 shares of the specialty pharmaceutical company’s stock worth $498,000 after purchasing an additional 124 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 3,500 shares of the company’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $140.00, for a total value of $490,000.00. Following the sale, the director owned 408,826 shares of the company’s stock, valued at approximately $57,235,640. This represents a 0.85% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Robert Iannone sold 7,159 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $168.26, for a total value of $1,204,573.34. Following the completion of the transaction, the executive vice president owned 72,628 shares of the company’s stock, valued at approximately $12,220,387.28. This represents a 8.97% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 18,659 shares of company stock worth $2,729,853. 4.30% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of analysts have weighed in on JAZZ shares. Wells Fargo & Company raised their price target on Jazz Pharmaceuticals from $170.00 to $235.00 and gave the company an “overweight” rating in a research note on Tuesday. Morgan Stanley boosted their target price on Jazz Pharmaceuticals from $185.00 to $205.00 and gave the stock an “overweight” rating in a research note on Monday. Zacks Research raised Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Friday, August 15th. Royal Bank Of Canada set a $194.00 price target on shares of Jazz Pharmaceuticals and gave the stock an “outperform” rating in a research note on Monday. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Jazz Pharmaceuticals in a research report on Wednesday, October 8th. Fourteen analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $195.07.

Jazz Pharmaceuticals Stock Down 2.5%

JAZZ opened at $176.08 on Thursday. The stock has a market capitalization of $10.70 billion, a P/E ratio of -26.16, a P/E/G ratio of 8.49 and a beta of 0.29. Jazz Pharmaceuticals PLC has a 12 month low of $95.49 and a 12 month high of $182.99. The business has a 50 day simple moving average of $136.90 and a 200-day simple moving average of $121.57. The company has a debt-to-equity ratio of 1.17, a current ratio of 1.62 and a quick ratio of 1.37.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, November 5th. The specialty pharmaceutical company reported $8.13 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.87 by $2.26. The company had revenue of $1.13 billion during the quarter, compared to the consensus estimate of $1.11 billion. Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period last year, the firm earned $6.54 EPS. Jazz Pharmaceuticals has set its FY 2025 guidance at 7.650-8.450 EPS. On average, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.